FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035962616> ?p ?o ?g. }

• W2035962616 endingPage "369" @default.
• W2035962616 startingPage "359" @default.
• W2035962616 abstract "Lorazepam is an anxiolytic, antidepressant agent, having suitable feature for transdermal delivery. The percutaneous permeation of lorazepam was investigated in rat skin after application of a water:propylene glycol (50:50%v/v). The enhancing effects of various surfactants (sodium lauryl sulfate (SLS), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride or Tween 80) with different concentrations on the permeation of lorazepam were evaluated using Franz diffusion cells fitted with rat skins. Flux, K(p), lag time and enhancement ratios (ERs) of lorazepam were measured over 24 h and compared with control sample. Furthermore, lorazepam solubility in presence of surfactants was determined. The in vitro permeation experiments with rat skin revealed that the surfactant enhancers varied in their ability to enhance the flux of lorazepam. The permeation profile of lorazepam in presence of the cationic surfactant, CTAB, reveals that an increase in the concentration of CTAB results in an increase in the flux of lorazepam in comparison with the control. But an increase in concentration of CTAB or benzalkounium chloride from 0.5 to 1% w/w or from 1 to 2.5% w/w resulted in a reduction in ER, respectively. Benzalkonium chloride which possessed the highest lipophilicity (logP=1.9) among cationic surfactants provided the greatest enhancement for lorazepam flux (7.66-fold over control) at 1% w/w of the surfactant. CTAB (logP<1) and sodium lauryl sulphate at a concentration of 5% w/w (the highest concentration) exhibited the greatest increase in flux of lorazepam compared with control (9.82 and 11.30-fold, respectively, over control). This is attributed to the damaging effect of the cationic and anionic surfactants on the skin at higher concentration. The results also showed that the highest ER was obtained in presence of 1% w/w surfactant with the exception of SLS and CTAB. The increase in flux at low enhancer concentrations is normally attributed to the ability of the surfactant molecules to penetrate the skin and increase its permeability. Reduction in the rate of transport of the drug present in enhancer systems beyond 1% w/w is attributed to the ability of the surfactant molecules to form micelles and is normally observed only if interaction between micelle and the drug occurs." @default.
• W2035962616 created "2016-06-24" @default.
• W2035962616 creator A5012599435 @default.
• W2035962616 creator A5023571572 @default.
• W2035962616 creator A5030033641 @default.
• W2035962616 creator A5035073798 @default.
• W2035962616 creator A5038113481 @default.
• W2035962616 creator A5047821806 @default.
• W2035962616 date "2003-01-01" @default.
• W2035962616 modified "2023-10-11" @default.
• W2035962616 title "The enhancement effect of surfactants on the penetration of lorazepam through rat skin" @default.
• W2035962616 cites W1481298312 @default.
• W2035962616 cites W1556919030 @default.
• W2035962616 cites W1965009765 @default.
• W2035962616 cites W1970558885 @default.
• W2035962616 cites W1976761724 @default.
• W2035962616 cites W1976904023 @default.
• W2035962616 cites W1977624927 @default.
• W2035962616 cites W1981674652 @default.
• W2035962616 cites W1986378994 @default.
• W2035962616 cites W1988982728 @default.
• W2035962616 cites W1992730162 @default.
• W2035962616 cites W1994807700 @default.
• W2035962616 cites W1996580678 @default.
• W2035962616 cites W2002174014 @default.
• W2035962616 cites W2003371745 @default.
• W2035962616 cites W2005637619 @default.
• W2035962616 cites W2008516597 @default.
• W2035962616 cites W2018063374 @default.
• W2035962616 cites W2021676731 @default.
• W2035962616 cites W2022029266 @default.
• W2035962616 cites W2033509406 @default.
• W2035962616 cites W2043625659 @default.
• W2035962616 cites W2062704583 @default.
• W2035962616 cites W2064833121 @default.
• W2035962616 cites W2065369943 @default.
• W2035962616 cites W2066990963 @default.
• W2035962616 cites W2070004038 @default.
• W2035962616 cites W2074832039 @default.
• W2035962616 cites W2079925168 @default.
• W2035962616 cites W2093685319 @default.
• W2035962616 cites W2100851327 @default.
• W2035962616 cites W2128404895 @default.
• W2035962616 cites W2150373324 @default.
• W2035962616 cites W2151282755 @default.
• W2035962616 cites W2204765880 @default.
• W2035962616 cites W22570928 @default.
• W2035962616 cites W2481049584 @default.
• W2035962616 cites W4255395780 @default.
• W2035962616 cites W4320301335 @default.
• W2035962616 cites W2094479467 @default.
• W2035962616 doi "https://doi.org/10.1016/s0378-5173(02)00554-9" @default.
• W2035962616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12527163" @default.
• W2035962616 hasPublicationYear "2003" @default.
• W2035962616 type Work @default.
• W2035962616 sameAs 2035962616 @default.
• W2035962616 citedByCount "137" @default.
• W2035962616 countsByYear W20359626162012 @default.
• W2035962616 countsByYear W20359626162013 @default.
• W2035962616 countsByYear W20359626162014 @default.
• W2035962616 countsByYear W20359626162015 @default.
• W2035962616 countsByYear W20359626162016 @default.
• W2035962616 countsByYear W20359626162017 @default.
• W2035962616 countsByYear W20359626162018 @default.
• W2035962616 countsByYear W20359626162019 @default.
• W2035962616 countsByYear W20359626162020 @default.
• W2035962616 countsByYear W20359626162021 @default.
• W2035962616 countsByYear W20359626162022 @default.
• W2035962616 countsByYear W20359626162023 @default.
• W2035962616 crossrefType "journal-article" @default.
• W2035962616 hasAuthorship W2035962616A5012599435 @default.
• W2035962616 hasAuthorship W2035962616A5023571572 @default.
• W2035962616 hasAuthorship W2035962616A5030033641 @default.
• W2035962616 hasAuthorship W2035962616A5035073798 @default.
• W2035962616 hasAuthorship W2035962616A5038113481 @default.
• W2035962616 hasAuthorship W2035962616A5047821806 @default.
• W2035962616 hasConcept C155574463 @default.
• W2035962616 hasConcept C178790620 @default.
• W2035962616 hasConcept C181389837 @default.
• W2035962616 hasConcept C185592680 @default.
• W2035962616 hasConcept C201399114 @default.
• W2035962616 hasConcept C2775919038 @default.
• W2035962616 hasConcept C2776300020 @default.
• W2035962616 hasConcept C2779706987 @default.
• W2035962616 hasConcept C41625074 @default.
• W2035962616 hasConcept C42219234 @default.
• W2035962616 hasConcept C43617362 @default.
• W2035962616 hasConcept C50670333 @default.
• W2035962616 hasConcept C55493867 @default.
• W2035962616 hasConcept C58226133 @default.
• W2035962616 hasConcept C71924100 @default.
• W2035962616 hasConcept C98274493 @default.
• W2035962616 hasConceptScore W2035962616C155574463 @default.
• W2035962616 hasConceptScore W2035962616C178790620 @default.
• W2035962616 hasConceptScore W2035962616C181389837 @default.
• W2035962616 hasConceptScore W2035962616C185592680 @default.
• W2035962616 hasConceptScore W2035962616C201399114 @default.
• W2035962616 hasConceptScore W2035962616C2775919038 @default.

• next